ArticleDiagnostics (Basel, Switzerland)2021
Cardiac Reverse Remodelling by 2D and 3D Echocardiography in Heart Failure Patients Treated with Sacubitril/Valsartan.
Article in Diagnostics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 17 citations in OpenAlex.
- Impacts of Sacubitril-Valsartan versus Valsartan on Left Ventricular Remodeling and Cardiac Function in Patients with Ischemic Heart Failure and Reduced Ejection Fraction: A Randomized Double-blinded Controlled Trial.Cardiovascular & hematological disorders drug targets · 2026Trial
- Early predicting improvement of severe systolic heart failure by left atrial volume.Heart and vessels · 2023Trial
- Sacubitril/Valsartan in Patients with HFrEF Undergoing Maintenance Hemodialysis, Evidence of Cardiac Reverse Remodeling During 12-Month Follow-Up: Case Series.Reports (MDPI) · 2026Article
- Effects of SGLT2 Inhibitors on Sleep Apnea Parameters and Cheyne-Stokes Respiration in Patients with Acute Decompensated Heart Failure: A Prospective Cohort Study.Biomedicines · 2025Article
- Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy.ESC heart failure · 2025Review
- Pharmacological Therapy of HFrEF in 2025: Navigating New Advances and Old Unmet Needs in An Eternal Balance Between Progress and Perplexities.Cardiac failure review · 2025Review
- Effects of sacubitril/valsartan on the functional capacity of real-world patients in Italy: the REAL.IT study on heart failure with reduced ejection fraction.Frontiers in cardiovascular medicine · 2024Article
- Editorial: Cardiac reverse remodeling after novel heart failure therapies.Frontiers in cardiovascular medicine · 2024Article
- Looking into the Kinetics of NT-proBNP and sST2 Changes in Patients with Heart Failure Treated with Sacubitril/Valsartan: A Hint to Different Therapeutic Pathways.Drugs in R&D · 2023Article
- Cardiac reverse remodelling by imaging parameters with recent changes to guideline medical therapy in heart failure.ESC heart failure · 2023Review
- Effects of sacubitril/valsartan on exercise capacity: a prognostic improvement that starts during uptitration.European journal of clinical pharmacology · 2023Article
- Dramatic disease regression in a case of HFrEF with end-stage renal failure treated with sacubitril/valsartan and SGLT2i.ESC heart failure · 2023Article
- Impact of Sacubitril/Valsartan on Circulating microRNA in Patients with Heart Failure.Biomedicines · 2023Article
- Effects of sacubitril/valsartan in ESRD patients undergoing hemodialysis with HFpEF.Frontiers in cardiovascular medicine · 2022Article
- Impact of Sacubitril/Valsartan on surfactant binding proteins, central sleep apneas, lung function tests and heart failure biomarkers: Hemodynamic or pleiotropism?Frontiers in cardiovascular medicine · 2022Article
- Impact of Angiotensin Receptor-Neprilysin Inhibitor Therapy on Cardiac Remodeling in Patients with Heart Failure and Reduced Ejection Fraction.Journal of cardiovascular echographyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In terms of sacubitril/valsartan (S/V)-induced changes in heart failure with reduced ejection fraction (HFrEF) via three-dimensional (3D) transthoracic echocardiography (TTE) and S/V effects based on HF aetiology, data are lacking. We prospectively enrolled 51 HFrEF patients (24 ischaemic, 27 non-ischaemic). At baseline and at 6-month follow-up (6MFU) after S/V treatment optimisation, we assessed the N-terminal pro-B-type natriuretic peptide (NT-proBNP), and cardiac remodelling by two-dimensional (2D) and 3DTTE. In non-ischaemic patients, 2D and 3DTTE showed an improvement in left ventricular (LV) size and biventricular function at 6MFU vs. baseline: 3D-LV end-diastolic volume (EDV) 103 ± 30 vs. 125 ± 32 mL/m
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.